Literature DB >> 27346574

CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas.

Mónica Pascual-García1, Cristina Bértolo1, Juan C Nieto2, Neus Serrat1, Íñigo Espinosa1, Emanuela D'Angelo1, Raquel Muñoz3, Ramón Rovira3, Silvia Vidal2, Jaime Prat4.   

Abstract

Carcinogenesis is a multistep process in which cancer cells and tumor stroma cells play important roles. T lymphocytes are immune constituents of tumor stroma and play a crucial function in anti-tumor response. By immunohistochemistry and flow cytometry, we studied T cytotoxic (CTLs) and T helper lymphocyte distribution and percentage in the tumor microenvironment and peripheral blood from 35 patients with endometrioid endometrial carcinomas (EEC). We also studied 23 healthy donors' blood samples as a control group. Tumor and non-tumoral endometrium samples were obtained. Immunohistochemistry revealed a high number of CTLs and T helper lymphocytes in the tumor stroma of myoinvasive EECs. T lymphocytes were mostly located in the invasive front. By flow cytometry, the percentages of CTLs and T helper lymphocytes were significantly higher in the tumor compared with the non-neoplastic endometrium (P = .0492 and P = .002). The mean fluorescence intensity of CD8 staining was lower in the tumor compared to the non-neoplastic endometrium (P = .001). There was also reduction of the mean fluorescence intensity of CD8 staining on peripheral blood from patients with grade 3 EECs compare to the peripheral blood from healthy donors (P = .0093). No alterations in the expression of granzymes A and B were found in the CTLs from the EEC cases. Finally, in a proteome profiler cytokine array we found that the growth differentiation factor 15 (GDF15) increased in blood in parallel to the tumor grade. EECs are capable of down-regulating CD8 expression of CTLs. Most likely, this effect is mediated by a soluble molecule present in plasma and is not a result of anergy or exhaustion state.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD8; Endometrial carcinoma; Flow cytometry; GDF15; T lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27346574     DOI: 10.1016/j.humpath.2016.05.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

Review 1.  Role of m6A modification in female infertility and reproductive system diseases.

Authors:  Jinyu Chen; Yiwei Fang; Ying Xu; Haotong Sun
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

2.  PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium.

Authors:  Lucie Bienfait; Nicky D'Haene; Xavier Catteau; Jean-Christophe Noël
Journal:  Case Rep Pathol       Date:  2018-05-03

3.  Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs.

Authors:  Caroline Dreis; Florian M Ottenlinger; Mateusz Putyrski; Andreas Ernst; Meik Huhn; Katrin G Schmidt; Josef M Pfeilschifter; Heinfried H Radeke
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

4.  Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis.

Authors:  Yuan Cheng; Xiaobo Zhang; Zhiqi Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

Review 5.  Extracellular Vesicles in Lung Cancer Metastasis and Their Clinical Applications.

Authors:  Michela Saviana; Giulia Romano; Patricia Le; Mario Acunzo; Patrick Nana-Sinkam
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

6.  Enhanced CXCR4 Expression of Human CD8Low T Lymphocytes Is Driven by S1P4.

Authors:  Tobias Burkard; Caroline Dreis; Martina Herrero San Juan; Meik Huhn; Andreas Weigert; Josef M Pfeilschifter; Heinfried H Radeke
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.